Immage Biotherapeutics Corp Analysis
Immage Biotherapeutics Corp is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Immage Biotherapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Immage Biotherapeutics Corp is worth, separate from its market price. There are two main types of Immage Biotherapeutics' stock analysis: fundamental analysis and technical analysis.
The Immage Biotherapeutics stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Immage Biotherapeutics' ongoing operational relationships across important fundamental and technical indicators.
Immage |
Immage Stock Analysis Notes
About 70.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.01. Immage Biotherapeutics had not issued any dividends in recent years. The entity had 273:1 split on the February 13, 2015. Immage Biotherapeutics Corp. does not have significant business operations. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited. IMMAGE BIOTHERAPEUTICS is traded on OTC Exchange in the United States. To learn more about Immage Biotherapeutics Corp call Zhi Mou at 866-692-2939 or check out http://www.immagebio.com.Immage Biotherapeutics Investment Alerts
| Immage Biotherapeutics is not yet fully synchronised with the market data | |
| Immage Biotherapeutics has some characteristics of a very speculative penny stock | |
| Immage Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.81, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immage Biotherapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (216.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immage Biotherapeutics Corp currently holds about 53.69 K in cash with (215.82 K) of positive cash flow from operations. | |
| Roughly 70.0% of the company shares are held by company insiders |
Immage Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 151.About Immage Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Immage Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immage shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Immage Biotherapeutics. By using and applying Immage Stock analysis, traders can create a robust methodology for identifying Immage entry and exit points for their positions.
Immage Biotherapeutics Corp. does not have significant business operations. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited. IMMAGE BIOTHERAPEUTICS is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Immage Biotherapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Immage Stock
If you are still planning to invest in Immage Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immage Biotherapeutics' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |